UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management

Not Applicable

Completed

Conditions: Type 2 Diabetes
Chronic Kidney Diseases

Interventions: Drug: Linagliptin
Drug: Glipizide

First Posted Date: 2015-11-18

Last Posted Date: 2018-10-12

Lead Sponsor: University of Washington

Target Recruit Count: 3

Registration Number: NCT02608177

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Phase 2

Completed

Conditions: Castration Levels of Testosterone
Castration-Resistant Prostate Carcinoma
Metastatic Prostate Carcinoma
Prostate Carcinoma Metastatic in the Bone
PSA Progression
Stage IV Prostate Cancer

Interventions: Drug: Carboplatin
Drug: Docetaxel
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-11-06

Last Posted Date: 2022-11-17

Lead Sponsor: University of Washington

Target Recruit Count: 14

Registration Number: NCT02598895

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

American Trial Using Tranexamic Acid in Thrombocytopenia

Phase 3

Completed

Conditions: Thrombocytopenia

Interventions: Drug: Placebo
Drug: Tranexamic Acid

First Posted Date: 2015-10-19

Last Posted Date: 2021-03-24

Lead Sponsor: University of Washington

Target Recruit Count: 330

Registration Number: NCT02578901

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Continuous Glucose Monitoring During and After Surgery

Not Applicable

Completed

Conditions: Diabetes

Interventions: Device: Continuous Glucose Monitor (CGM)

First Posted Date: 2015-10-09

Last Posted Date: 2023-08-31

Lead Sponsor: University of Washington

Target Recruit Count: 10

Registration Number: NCT02572856

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Stage IV Prostate Cancer AJCC v7
Metastatic Malignant Neoplasm in the Bone
Metastatic Prostate Carcinoma
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Carboplatin
Drug: Docetaxel
Other: Laboratory Biomarker Analysis
Drug: Sirolimus

First Posted Date: 2015-10-01

Last Posted Date: 2021-10-01

Lead Sponsor: University of Washington

Target Recruit Count: 28

Registration Number: NCT02565901

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Not Applicable

Completed

Conditions: Refractory Acute Lymphoblastic Leukemia
Recurrent Acute Leukemia of Ambiguous Lineage
Recurrent Acute Myeloid Leukemia
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Refractory Acute Leukemia of Ambiguous Lineage

Interventions: Other: Chemosensitivity Assay
Other: Cytology Specimen Collection Procedure
Genetic: Gene Expression Analysis
Genetic: Genetic Variation Analysis
Drug: In Vitro Sensitivity-Directed Chemotherapy

First Posted Date: 2015-09-16

Last Posted Date: 2022-06-30

Lead Sponsor: University of Washington

Target Recruit Count: 34

Registration Number: NCT02551718

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Stroke and CPAP Outcome Study: A Sham-controlled Trial of CPAP Among Stroke Rehabilitation Patients

Phase 1

Completed

Conditions: Stroke
Sleep Apnea, Obstructive

Interventions: Device: Auto-titrating CPAP
Device: Sham-CPAP

First Posted Date: 2015-09-16

Last Posted Date: 2021-01-13

Lead Sponsor: University of Washington

Target Recruit Count: 40

Registration Number: NCT02551757

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

Phase 1

Completed

Conditions: Stage I Follicular Lymphoma
Stage II Diffuse Large B-Cell Lymphoma
Stage III Diffuse Large B-Cell Lymphoma
Stage III Follicular Lymphoma
Composite Lymphoma
Grade 3b Follicular Lymphoma
Stage I Diffuse Large B-Cell Lymphoma
Stage II Follicular Lymphoma
Stage IV Diffuse Large B-Cell Lymphoma
Stage IV Follicular Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2015-09-04

Last Posted Date: 2020-10-14

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT02541565

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Head and Neck Squamous Cell Carcinoma
Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Recurrent Nasopharynx Carcinoma
Recurrent Salivary Gland Carcinoma
Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary
Stage III Major Salivary Gland Carcinoma
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Stage III Nasopharyngeal Carcinoma
Stage IV Nasopharyngeal Carcinoma
Stage IVA Major Salivary Gland Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Drug: Vorinostat

First Posted Date: 2015-09-02

Last Posted Date: 2024-11-26

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT02538510

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients

Not Applicable

Recruiting

Conditions: Tricuspid Regurgitation
Heart Failure NYHA Class III
Heart Failure NYHA Class IV

Interventions: Device: Left ventricular assist device (LVAD)
Procedure: Tricuspid Valve Repair (TVR)

First Posted Date: 2015-09-02

Last Posted Date: 2021-02-23

Lead Sponsor: University of Washington

Target Recruit Count: 40

Registration Number: NCT02537769

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

Home Terms & Conditions Privacy Policy